Promoting Radon Testing Among Mothers of Young Children

May 12, 2026 updated by: Soojung Kim, University of North Dakota

Promoting Radon Testing Among Mothers of Young Children: A Translational Clinical Trial

Radon is the second-leading cause of lung cancer after smoking and may contribute to other cancer deaths; children are especially vulnerable due to a larger lung surface area and higher respiratory rates. The goal of this research is to test the feasibility of the radon app to promote radon testing among mothers of children aged 4 or younger when they receive a free radon test kit.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This feasibility study enrolls mothers of children under age 4 who receive a free short-term radon test kit. Participants are introduced to and given access to a smartphone radon app designed to deliver targeted education, step-by-step testing instructions, reminders, and social-sharing prompts. The study measures cognitive outcomes (radon knowledge, self-efficacy for testing, and response efficacy beliefs) before and after app exposure, and behavioral outcomes (whether the test kit is completed and returned for lab analysis, and whether participants share radon information or recommend testing to others). Data collection combines brief baseline and follow-up surveys, app usage analytics (e.g., time in app, modules completed, reminder interactions), and laboratory confirmation of returned kits. Feasibility metrics include recruitment and retention rates, app engagement, and kit return rates.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
100

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.
  • Name: Soojung Kim Interim Dean, School of Graduate Studies, PhD, MPH
  • Phone Number: 701-777-2786
  • Email: soojung.kim@UND.edu

Study Locations

  • United States
    • North Dakota
      • Bismarck, North Dakota, United States, 58501
        • Recruiting
        • University of North Dakota Center for Family Medicine, Bismarck Clinic
        • Contact:
      • Minot, North Dakota, United States, 58701
        • Recruiting
        • University of North Dakota Center for Family Medicine, Minot Clinic
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Participants are female mothers of children aged 4 and under.
  • Participants own a smartphone.
  • Children brought in for appointments are their biological or adoptive child.

Exclusion Criteria:

  • Previous testing for radon within the past two (2) years.
  • The mother's child brought in for the appointment is over 4 years of age.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: The radon app
Participants will be encouraged to download the radon app and asked to use the radon app for four months where they will be exposed to mobile friendly educational content that is created from educational print brochures about radon published by EPA.
Behavioral: The radon app
Participants will be asked to use the radon app.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
T1 (baseline: pre-exposure survey, distribution of free radon test kit)
Time Frame: Initial Enrollment to 2 months after enrollment
T1 (baseline: pre-exposure survey, distribution of free radon test kit). The pre-expsosure survey will measure: Primary endpoints: (1) Radon knowledge, 20 true/false items); (2) self-efficacy, response efficacy, and sharing intention (7-point Likert).
Initial Enrollment to 2 months after enrollment
T2 (post-exposure survey at 2 months)
Time Frame: 2 months after enrollment
T2 refers to the time point where participants will complete the post-exposure survey, which will happen two months after T1. The primary endpoints are: (1) Changes in radon knowledge from T1 to T2, as measured by the number of correct responses to a series of 20 true/false questions (e.g., "The EPA recommends that homes with 4 picocuries per liter (pCi/L) or more of radon should be fixed."); (2) Changes in self-efficacy, response efficacy, and sharing intention from T1 to T2, measured by 7-point Likert scales; (3) Radon information shared with others and recommended to others to test their houses for radon from T1 to T2. It will be measured by a series of yes/no questions. Analyses: Aim 1-directional dependent t-tests for mean changes; McNemar's test for paired proportions of sharing.
2 months after enrollment
T3 (end of kit tracking at 4 months)
Time Frame: 4 months after last enrollment
Number of radon test kits used and returned to the laboratory by participants. Directional McNemar's test for kit return proportions T1 vs T3.
4 months after last enrollment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of North Dakota

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
National Institute of General Medical Sciences (NIGMS)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 10, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 7, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 12, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 15, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 15, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 12, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • IRB0006486
  • 5P20GM155890-02 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings